Harvard Bioscience
HBIO
94 hedge funds and large institutions have $84.2M invested in Harvard Bioscience in 2024 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 33 increasing their positions, 27 reducing their positions, and 18 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 27
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.15% less ownership
Funds ownership: 7.32% → 7.17% (-0.15%)
6% less funds holding
Funds holding: 100 → 94 (-6)
7% less capital invested
Capital invested by funds: $90.7M → $84.2M (-$6.51M)
33% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 18
92% less call options, than puts
Call options by funds: $2K | Put options by funds: $26K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AE
AMH Equity
Great Neck,
New York
|
+$557K |
| 2 |
HP
Harvey Partners
Tarrytown,
New York
|
+$464K |
| 3 |
Goldman Sachs
New York
|
+$287K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$279K |
| 5 |
Morgan Stanley
New York
|
+$278K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
-$591K |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$564K |
| 3 |
Millennium Management
New York
|
-$402K |
| 4 |
GC
Globeflex Capital
San Diego,
California
|
-$398K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$359K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Squarepoint
New York
| – | -$56K | -1,965 | Closed |
|
|
GI
102
GAMCO Investors
Greenwich,
Connecticut
| – | -$42.8K | -1,500 | Closed |
|
|
CSS
103
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$40.3K | -1,414 | Closed |
|
|
PTC
104
Petrus Trust Company
Dallas,
Texas
| – | -$39.3K | -1,380 | Closed |
|
|
PCM
105
Portolan Capital Management
Boston,
Massachusetts
| – | -$34.2K | -1,200 | Closed |
|
106
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$28.5K | -1,002 | Closed |
|
|
PD
107
Point72 (DIFC)
Dubai,
United Arab Emirates
| – | -$6.92K | -243 | Closed |
|
|
IC
108
Innealta Capital
Austin,
Texas
| – | -$4.76K | -167 | Closed |
|
|
PAS
109
Point72 Asia (Singapore)
Singapore
| – | -$4.74K | -166 | Closed |
|
|
SSG
110
Summit Securities Group
New York
| – | -$1K | -31 | Closed |
|
111
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$160 | -6 | Closed |
|
HBIO Hedge Fund Activity: Q3 2024 in Review
94 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q3 2024, worth a combined $84.2M — down 7.2% from $90.7M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of HBIO and 12 opened new positions — a net loss of 6 holders — while 27 trimmed existing stakes and 33 added.
The largest buyer was AMH Equity, adding an estimated $557K. The largest seller was Boston Partners, exiting entirely with an estimated $591K sold.
- 94 institutional investors held Harvard Bioscience (HBIO) as of Q3 2024, down from 100 in Q2 2024.
- Funds reported $84.2M of Harvard Bioscience stock for Q3 2024, down 7.2% quarter-over-quarter.
- 12 funds opened new Harvard Bioscience positions in Q3 2024 and 18 closed out, a net change of -6 holders.
- The largest Harvard Bioscience buyer in Q3 2024 was AMH Equity, an estimated $557K added.
- The largest Harvard Bioscience seller in Q3 2024 was Boston Partners, an estimated $591K sold.
Based on aggregated 13F filings for Q3 2024.